Sign up to save your podcasts
Or
Share The Long Run with Luke Timmerman
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Long Run with Luke Timmerman
By Timmerman ReportScience
Based on Podcast App listening data
The Long Run with Luke Timmerman episodes
- Ep213: Daphne Koller on The Moment in AI Drug DiscoveryDaphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.1 hr 5 min
- Ep212: Tim Shannon on Creating Targeted Protein Degraders as MedicinesTim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.1 hr 15 min
- Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in NeuroscienceArden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.1 hr 7 min
- Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune DisordersCameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.1 hr 4 min
- Ep209: Mathai Mammen on Developing Drugs Against Undruggable TargetsMathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.1 hr 37 min
- Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr VirusGary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.1 hr 8 min
- Ep207: Jason Coloma on Genetic Medicines for Kidney DiseasesJason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.1 hr 18 min
- Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung DiseasesLyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.1 hr 8 min
- Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick WithHeather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.1 hr 9 min
- Ep204: Troy Wilson on Precision Cancer Drugs and CombosTroy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.1 hr 8 min
About The Long Run with Luke Timmerman
From the publisher's feed
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
More shows like The Long Run with Luke Timmerman
Freakonomics Radio
31,943 Listeners
Odd Lots
1,958 Listeners
The a16z Show
1,089 Listeners
About Men Radio
15 Listeners
The Bio Report
39 Listeners
How I Built This with Guy Raz
30,106 Listeners
POP | TECH | JAM
78 Listeners
Strings and Things
5 Listeners
The Readout Loud
338 Listeners
The Journal.
6,071 Listeners
Biotech 2050 Podcast
62 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,150 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Raising Health
149 Listeners
Biotech Hangout
20 Listeners
The BioCentury Show
11 Listeners
The Workup
0 Listeners
Cheeky Pint
62 Listeners